LGM
CBIO

Logos Global Management’s Crescent Biopharma CBIO Stock Holding History

Logos Global Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.2M Buy
1,900,000
+1,417,500
+294% +$27.7M 1.47% 24
2026
Q1 		$8.86M Sell
482,500
-117,500
-20% -$1.35M 0.44% 49
2025
Q4 		$7.12M Hold
600,000
– – 0.43% 48
2025
Q3 		$7.13M Buy
600,000
+46,314
+8% +$614K 0.64% 41
2025
Q2 		$8.94M Buy
553,686
+499,686
+925% +$10.6M 0.99% 33
2025
Q1 		$1.13M Hold
54,000
– – 0.2% 34
2024
Q4 		$1.34M Buy
+54,000
New +$1.47M 0.16% 46

Other funds holding CBIO

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Logos Global Management's CBIO Position: Q2 2026 in Review

Logos Global Management increased its Crescent Biopharma (CBIO) stake by 294% in Q2 2026, buying an estimated $27.7M and bringing the position to 1,900,000 shares worth $34.2M. The position accounts for 1.47% of the portfolio, ranked #24.

Logos Global Management first reported a position in CBIO in Q4 2024 and has held it in 7 quarters since. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Logos Global Management held 1,900,000 shares of Crescent Biopharma worth $34.2M as of Q2 2026.
  • Logos Global Management bought 1,417,500 Crescent Biopharma shares in Q2 2026, an estimated $27.7M.
  • Crescent Biopharma made up 1.47% of Logos Global Management's portfolio in Q2 2026, its #24 holding.
  • Logos Global Management first reported a position in Crescent Biopharma in Q4 2024 and has held it in 7 quarters since.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.